Sinovac Biotech Ltd. (AMEX: SVA)
Sinovac Biotech Ltd. (SVA) is an emerging China-based biotechnology company focused on the development, manufacturing and commercialization of human vaccines against infectious diseases. The Company’s portfolio of products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses. Its PanfluTM vaccine, which protects against the H5N1 influenza virus, has already been approved for government stockpiling.
The Company is also developing human vaccines for Enterovirus 71 (EV71), Japanese encephalitis and rabies. SVA is the first company in the world to have been granted permission to begin clinical trials for a vaccine to prevent Severe Acute Respiratory Syndrome (SARS), and the only company in China to develop a human use avian flu vaccine and successfully obtain the production approval from Chinese government.
Popularity: unranked [?]
